Murashima Miho, Hamano Takayuki, Abe Masanori, Masakane Ikuto
Department of Nephrology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
Nephrol Dial Transplant. 2023 Sep 29;38(10):2143-2151. doi: 10.1093/ndt/gfad019.
BACKGROUND: Outcomes of a combination of peritoneal dialysis (PD) and once-weekly haemodialysis (PD + HD) have not been extensively studied. METHODS: This prospective cohort study using the Japanese Society for Dialysis Therapy Renal Data Registry included those who transitioned from PD to PD + HD therapy or thrice-weekly HD from 2011 to 2018. Exposure was PD + HD therapy compared with thrice-weekly HD. The outcome was time to all-cause or cause-specific death. Associations between PD + HD therapy and outcomes were examined by Cox regression. Sensitivity analyses were performed by propensity score (PS) matching, PS matching with a shared frailty model in which dialysis facilities were treated as a random effect, inverse probability weighting (IPW), PS adjustment, PS stratification, competing risk regression and on-treatment analyses in which data were censored at the transition to thrice-weekly HD for those on PD + HD therapy. RESULTS: During the study period, 1001 subjects transitioned to PD + HD therapy and 2031 to thrice-weekly HD. During a median follow-up of 3.5 years, 575 subjects died. All-cause, cardiovascular, congestive heart failure-related or infection-related mortality were not significantly different between those on PD + HD and those on thrice-weekly HD [hazard ratio 0.95 (95% confidence interval 0.78-1.16), 1.26 (0.92-1.72), 1.24 (0.77-1.99) and 0.89 (0.57-1.39), respectively]. Sensitivity analyses yielded similar results except that PD + HD therapy was associated with significantly lower all-cause mortality by PS adjustment and PS matching with the shared frailty model and lower infection-related mortality by PS adjustment and IPW. CONCLUSIONS: PD + HD therapy was associated with similar or potentially lower mortality compared with thrice-weekly HD. Considering a flexible lifestyle, PD + HD therapy could be a great option.
背景:腹膜透析(PD)与每周一次血液透析(PD + HD)联合治疗的效果尚未得到广泛研究。 方法:这项前瞻性队列研究使用了日本透析治疗学会肾脏数据登记处的数据,纳入了2011年至2018年期间从PD转为PD + HD治疗或每周三次血液透析的患者。暴露组为接受PD + HD治疗的患者,对照组为接受每周三次血液透析的患者。观察终点为全因死亡或特定病因死亡时间。采用Cox回归分析PD + HD治疗与观察终点之间的关联。通过倾向评分(PS)匹配、将透析机构视为随机效应的共享脆弱模型的PS匹配、逆概率加权(IPW)、PS调整、PS分层、竞争风险回归以及对接受PD + HD治疗的患者在转为每周三次血液透析时进行数据截尾的治疗中分析等方法进行敏感性分析。 结果:在研究期间,1001名受试者转为PD + HD治疗,2031名受试者转为每周三次血液透析。在中位随访3.5年期间,575名受试者死亡。接受PD + HD治疗的患者与接受每周三次血液透析的患者在全因、心血管、充血性心力衰竭相关或感染相关死亡率方面无显著差异[风险比分别为0.95(95%置信区间0.78 - 1.16)、1.26(0.92 - 1.72)、1.24(0.77 - 1.99)和0.89(0.57 - 1.39)]。敏感性分析得出了类似的结果,但通过PS调整和共享脆弱模型的PS匹配,PD + HD治疗与显著较低的全因死亡率相关,通过PS调整和IPW与较低的感染相关死亡率相关。 结论:与每周三次血液透析相比,PD + HD治疗的死亡率相似或可能更低。考虑到生活方式的灵活性,PD + HD治疗可能是一个很好的选择。
Nephrol Dial Transplant. 2022-11-23
Nephrol Dial Transplant. 2021-1-25
Nephrol Dial Transplant. 2018-8-1
Nephrol Dial Transplant. 2011-5-28
Am J Kidney Dis. 2016-12-10
Rev Cardiovasc Med. 2024-6-25
Cochrane Database Syst Rev. 2024-6-20